Ouachita Baptist University Scholarly Commons @ Ouachita

Scholars Day Conference

Scholars Day 2021

Apr 21st, 3:10 PM - 3:25 PM

Defying the Darkness: Countering Cancer with Porphyrins and Lights

Travis Hankins *Ouachita Baptist University*

Follow this and additional works at: https://scholarlycommons.obu.edu/scholars_day_conference

Part of the Medical Sciences Commons

Hankins, Travis, "Defying the Darkness: Countering Cancer with Porphyrins and Lights" (2021). *Scholars Day Conference*. 6. https://scholarlycommons.obu.edu/scholars_day_conference/2021/honors_theses/6

This Presentation is brought to you for free and open access by the Carl Goodson Honors Program at Scholarly Commons @ Ouachita. It has been accepted for inclusion in Scholars Day Conference by an authorized administrator of Scholarly Commons @ Ouachita. For more information, please contact mortensona@obu.edu.


Defying the Darkness: Countering Cancer with Light A Senior Thesis by Travis Hankins

1. Background

- 2. Synthesis
- 3. Purification and Characterization
- 4. Metabolic Analysis
- 5. Conclusions and Future Work

What's the Focus?

- This research focused on treating Triple-Negative Breast Cancer (TNBC)
 - TNBC tests negative for normal receptors in breast cancer
 - Many current treatments rely on these receptors
- Design compound that can work without cell receptors




• "Triple-Negative Breast Cancer." Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 14 Sept. 2020, www.cdc.gov/cancer/breast/triple-negative.htm.

• "Triple-Negative Breast Cancer." YouTube, National Breast Cancer Foundation, Inc., 4 Sept. 2012, youtu.be/oAp4ZKbZU38.

What is Photodynamic Therapy?


- Photodynamic Therapy (PDT): treatment of cancer using light and a photosensitive compound
 - Advantages less invasive, fewer side effects
 - Disadvantages relies on access to light, light sensitivity



- "Photodynamic Therapy for Cancer." National Cancer Institute, National Institutes of Health, 6 Sept. 2011, www.cancer.gov/about-cancer/treatment/types/surgery/photodynamic-fact-sheet.
- "Getting Photodynamic Therapy." Radiation Therapy, American Cancer Society, 2 Mar. 2020, www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation/photodynamic-therapy.html.
- Reynolds, Tom. "Photodynamic Therapy Expands Its Horizons." JNCI: Journal of the National Cancer Institute, vol. 89, no. 2, 1997, pp. 112–114., doi:10.1093/jnci/89.2.112.

What are Porphyrins?

- Porphyrins: large, cyclic molecules
 - Most widely known is heme, a component in hemoglobin
 - Chlorophyll Mg-containing porphyrin
- Highly versatile and stable due to bond conjugation
- Research aimed to produce a novel porphyrin that is a PDT agent




Structure of Porphin, one of the simplest porphyrins

Project Goals


- Synthesize, purify, characterize, and test a novel porphyrin derivative
- To be a viable photodynamic agent:
 - The porphyrin should be water soluble
 - The porphyrin should be able to kill cells in low concentrations when exposed to light
 - The porphyrin should have a minimal effect on cells when not exposed to light

Background Synthesis Purification and Characterization Metabolic Analysis Conclusions and Future Work

Synthesis of H₂TPPC




Synthesis of the Acid Chloride Porphyrin



H₂TPPC

Acid Chloride Porphyrin

Synthesis of H₂TPP-MorphMeOH



Background Synthesis Purification and Characterization Metabolic Analysis Conclusions and Future Work

Product Purification


- The final product was purified three ways: syringe filtration, Sephadex LH-20, and Sephadex G-50
 - Syringe eliminate coarse particulate
 - LH-20 lipophilicity
 - G-50 molecular size



• "Millex Syringe Filter, Nylon, Non-Sterile SLGN033." Millipore Sigma, Sigma Aldrich, www.sigmaaldrich.com/catalog/product/mm/slgn033?lang=en®ion=US

IR Spectroscopy


- Sample exposed to range of IR light, monitor how much of each wavelength is transmitted
- Certain bonds absorb certain wavelengths and begin vibrating in response → transmittance decreases
- Spectrum is used to identify functionalities



• Infrared (IR) Spectroscopy. 30 May 2020, https://chem.libretexts.org/@go/page/45256.


IR Spectroscopy

R =



NMR Spectroscopy

- Sample hit with an electromagnetic pulse, causing the production of signals
- Signals are interpreted by the detector and turned into a spectrum
- Spectrum is used to elucidate structures




NMR Spectroscopy


H

H

R = -




UV-Vis Spectroscopy



Peaks (nm)	Molar Absorptivity Coefficient, ε (cm ⁻¹ mM ⁻¹)
413	120
518	5.35
555	2.93
581	2.45
636	1.95

High-Performance Liquid Chromatography

 Purity is based on area of chromatogram that corresponds to the compound – the purity of H₂TPP-MorphMeOH was determined to be 98%



Background
Synthesis
Purification and Characterization
Metabolic Analysis
Conclusions and Future Work

MTT Analysis

- MTT analysis method of determining viability based on cell metabolic activity.
- Several concentrations of the compound were tested across two plates; one was kept in the dark, and the other exposed to light.
- Compound efficacy was determined using LD₅₀





Plate kept in the dark – consistent, deep purple color

Plate exposed to light – color lessens as porphyrin concentration increases and cell death occurs

MTT Results for H₂TPP-MorphMeOH

Plated concentrations: 0, 1, 3, 10, 30 and 100 µM Plated concentrations: 0, 50, 100, 150, 200, and 250 µM



Background Synthesis Purification and Characterization Metabolic Analysis Conclusions and Future Work

Project Review

- The novel porphyrin H₂TPP-MorphMeOH was successfully synthesized from H₂TPPC and the amine morpholin-2-yl methanol
 - The product was successfully purified (HPLC)
 - The product retained internal structure (UV-Vis, NMR)
 - The product coupled with the amine (NMR, IR)
- H₂TPP-MorphMeOH was determined to be a weak antineoplastic agent based on the results of the MTT assays

Project Goals (Revisited)

- Synthesize, purify, characterize, and test a novel porphyrin derivative
- To be a viable photodynamic therapy agent:
 - The porphyrin should be water soluble
 - The porphyrin should be able to kill cells in low concentrations when exposed to light
 - The porphyrin should have minimal effect on cells when not exposed to light
- Since H₂TPP-MorphMeOH doesn't satisfy all three requirements, it would not be fit as a PDT agent

Future Work

- Re-perform second MTT assay to resolve error
- Continue exploring H₂TPP-MorphMeOH's potential uses
- Continue searching for and developing other porphyrin derivatives

Special Thanks

- Dr. Joseph Bradshaw
- Dr. Timothy Hayes
- Dr. Amy Sonheim
- Catherine Shirley
- Alexander Podguzov
- Patterson Summer Research Program
- J.D. Patterson School of Natural Sciences

